Advancements in tyrosine kinase inhibitors [1], novel agents such as blinatumomab [2], and allogeneic hematopoietic cell transplantation (allo-HCT) have improved the survival of patients with Philadelphia chromosome (Ph)-positive acute…
Poor prognostic implication of CDKN2 deletion in adult patients with Philadelphia chromosome-positive ALL
